Increasing of FKBP9 can predict poor prognosis in patients with prostate cancer

Fu-Neng Jiang; Li-Jun Dai; Sheng-Bang Yang; Yong-Ding Wu; Yu-Xiang Liang; Xiao-Li Yin; Cui-Yun Zou; Wei-de Zhong

doi:10.1016/j.prp.2019.152732

Increasing of FKBP9 can predict poor prognosis in patients with prostate cancer

Pathol Res Pract. 2020 Jan;216(1):152732. doi: 10.1016/j.prp.2019.152732. Epub 2019 Nov 11.

Authors

Fu-Neng Jiang¹, Li-Jun Dai², Sheng-Bang Yang³, Yong-Ding Wu⁴, Yu-Xiang Liang⁵, Xiao-Li Yin⁶, Cui-Yun Zou⁷, Wei-de Zhong⁸

Affiliations

¹ Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China. Electronic address: [email protected].
² Laboratory Animal Center, Guangzhou Medical University, Guangzhou 510182, China. Electronic address: [email protected].
³ Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China. Electronic address: [email protected].
⁴ Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China. Electronic address: [email protected].
⁵ Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China. Electronic address: [email protected].
⁶ Guangzhou HYY Precision&Translation Medicine Institute, Guangzhou 510300, China. Electronic address: [email protected].
⁷ Guangzhou HYY Precision&Translation Medicine Institute, Guangzhou 510300, China. Electronic address: [email protected].
⁸ Department of Urology, Guangdong Key Laboratory of Clinical Molecular Medicine and Diagnostics, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, 510180, China. Electronic address: [email protected].

PMID: 31780055
DOI: 10.1016/j.prp.2019.152732

Abstract

Background: FK506 binding protein 9 (FKBP9) has been reported and identified for a long time, but its relationship with cancer is rarely studied. For example, the role of FK506 binding protein 9 in prostate cancer (PCa) is still unclear. Therefore, we decided to detect the expression level of FKBP9 in PCa and explore its clinical significance.

Methods: The expression level of FKBP9 protein was detected by immunohistochemistry. In addition, it was demonstrated by high-throughput sequencing of mRNA levels in the TCGA (cancer genome atlas) dataset of 499 patients. Kaplan-meier analysis and Cox proportional hazard regression model were used to evaluate the relationship between FKBP9 expression and survival in prostate cancer patients.

Results: The expression of FKBP9 was localized in the cytoplasm, which in normal prostate tissues was obviously lower than that in PCa tissues (P = 0.001). High expression of FKBP9 was related with lymph node metastasis (P = 0.022) and distant metastasis (P = 0.028). Kaplan-Meier survival analysis revealed that the BCR-free survival of PCa patients with high FKBP9 level was significantly shortened (P=0.041).

Conclusions: FKBP9 may be a cancer promoter that enhances PCa progression, and the level of FKBP9 may be used as an independent precursor of PCa patients.

Keywords: FKBP9; Prognosis; Prostate cancer.

MeSH terms

Aged
Disease Progression
Gene Expression Regulation, Neoplastic / genetics*
Humans
Lymphatic Metastasis / pathology
Male
Middle Aged
Prognosis
Proportional Hazards Models
Prostate / metabolism*
Prostate / pathology
Prostatic Neoplasms / genetics
Prostatic Neoplasms / metabolism*
Prostatic Neoplasms / pathology
Tacrolimus Binding Proteins / metabolism*

Substances

FKBP9 protein, human
Tacrolimus Binding Proteins